RITUXIMAB

Clinical trials for RITUXIMAB explained in plain language.

Never miss a new study

Get alerted when new RITUXIMAB trials appear

Sign up with your email to follow new studies for RITUXIMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo aims to wipe out lingering cancer cells in aggressive lymphoma

Disease control Not yet recruiting

This study is testing if adding a drug called glofitamab after standard initial treatment can better control a fast-growing type of blood cancer called mantle cell lymphoma (MCL). It is for adults newly diagnosed with a high-risk form of MCL who have not yet started treatment. Th…

Matched conditions: RITUXIMAB

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

RITUXIMAB

Get alerted when new RITUXIMAB trials appear

New drug combo aims to wipe out lingering cancer cells in aggressive lymphoma